神经内分泌肿瘤（NENs）的心脏转移的检测频率不断增加，然而最佳的成像策略仍不清楚。我们进行了一项单中心回顾性研究，探讨了生长抑素受体正电子发射计算机断层扫描/计算机断层扫描（SSTR PET/CT）和心脏磁共振成像（CMR）在NEN心脏转移中的作用，确定了这些成像技术所得结果的一致程度，并检查了每种成像技术的优缺点。次要目标是确定心脏转移是否与肽受体放射性核素治疗（PRRT）期间的不良心脏事件相关。识别了19例NEN心脏转移患者。对电子病历进行了回顾性复查，并且如果有的话，SSTR PET/CT和CMR由成像专家进行了盲目复查，记录心脏转移的数量和位置。所有19名患者都进行了SSTR PET/CT检查，其中10名患者进行了CMR检查。SSTR PET/CT检测到的转移比CMR多。在CMR上识别时，转移更准确定位。12名患者接受了PRRT治疗，没有发生心脏不良反应。SSTR PET/CT和CMR在NEN心脏转移的成像中是互补的检查。SSTR PET/CT在病变检测方面更敏感，CMR在病变表征方面更好。这两种检查提供了有用的信息用于治疗计划，包括PRRT的安全施行。© 2023. 作者。

Cardiac metastases from neuroendocrine neoplasms (NENs) are being detected with increasing frequency, although the optimal imaging strategy remains unclear. We performed a single-center retrospective study to explore the role of somatostatin receptor positron emission tomography/computed tomography (SSTR PET/CT) and cardiac magnetic resonance imaging (CMR) in NEN cardiac metastases, determine the degree of concordance between the findings of these imaging modalities, and examine the advantages and disadvantages of each imaging technique. A secondary aim was to determine if cardiac metastases were associated with adverse cardiac events during peptide receptor radionuclide therapy (PRRT).19 patients with NEN cardiac metastases were identified. A retrospective review of electronic medical records was performed, and if available SSTR PET/CT and CMR were blindly re-reviewed by imaging specialists, documenting the number and location of cardiac metastases. All 19 patients had SSTR PET/CT, and 10/19 patients had CMR. SSTR PET/CT identified more metastases than CMR. When identified on CMR, metastases were more accurately localized. 12/19 patients received PRRT, with no cardiac adverse effects.SSTR PET/CT and CMR are complementary investigations in the imaging of NEN cardiac metastases. SSTR PET/CT appears more sensitive for lesion detection, and CMR offers better lesion characterization. Both investigations present useful information for the planning of treatment including PRRT, which was administered safely.© 2023. The Author(s).